tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Positive Market Trajectory and Promising Developments Drive Buy Rating for Nuvation Bio
PremiumRatingsPositive Market Trajectory and Promising Developments Drive Buy Rating for Nuvation Bio
1M ago
Promising Outlook for Nuvation Bio: Buy Rating Backed by Ibtrozi’s Market Success and Future Prospects
Premium
Ratings
Promising Outlook for Nuvation Bio: Buy Rating Backed by Ibtrozi’s Market Success and Future Prospects
1M ago
Nuvation Bio’s Phase 2 Study on Safusidenib: A Potential Breakthrough for IDH1 Mutant Glioma
Premium
Company Announcements
Nuvation Bio’s Phase 2 Study on Safusidenib: A Potential Breakthrough for IDH1 Mutant Glioma
2M ago
Nuvation Bio announces taletrectinib as preferred agent in NCCN Guidelines
PremiumThe FlyNuvation Bio announces taletrectinib as preferred agent in NCCN Guidelines
3M ago
Nuvation Bio price target lowered to $6 from $10 at RBC Capital
Premium
The Fly
Nuvation Bio price target lowered to $6 from $10 at RBC Capital
3M ago
Buy Rating for Nuvation Bio’s IBTROZI: FDA Approval and Competitive Edge in ROS1+ NSCLC Treatment
Premium
Ratings
Buy Rating for Nuvation Bio’s IBTROZI: FDA Approval and Competitive Edge in ROS1+ NSCLC Treatment
3M ago
Nuvation Bio announces FDA approval of Ibtrozi for advanced ROS-1+ NSCLC
PremiumThe FlyNuvation Bio announces FDA approval of Ibtrozi for advanced ROS-1+ NSCLC
3M ago
Nuvation Bio trading halted, news pending
Premium
The Fly
Nuvation Bio trading halted, news pending
3M ago
FDA announces apporval of Nuvation Bio’s Ibtrozi for lung cancer
Premium
The Fly
FDA announces apporval of Nuvation Bio’s Ibtrozi for lung cancer
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100